DaVita (NYSE:DVA) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded DaVita to “Hold” from “Buy.” Analyst sentiment remains a “Moderate Buy” overall, with four Buy ratings and three Holds and an average price target of $233.43.
• DaVita exceeded quarterly expectations, reporting $3.82 in EPS versus a $3.57 consensus and $3.58 billion in revenue, up 4.6% year over year.
• The stock opened at $187.18, while profitability concerns—including a decline in operating profit and cash flow—plus a reported China-related charge and investor investigation add uncertainty.

DaVita (NYSE:DVA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

DVA has been the subject of a number of other research reports. Truist Financial dropped their price objective on shares of DaVita from $250.00 to $215.00 and set a "hold" rating for the company in a research note on Friday, August 7th. Weiss Ratings upgraded shares of DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Friday, October 9th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $265.00 target price on shares of DaVita in a research note on Wednesday, August 5th. TD Cowen restated a "buy" rating on shares of DaVita in a research note on Wednesday, October 21st. Finally, Oppenheimer set a $220.00 price objective on DaVita in a report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $233.43.

DaVita Stock Performance

NYSE DVA opened at $187.18 on Friday. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49. The stock has a market cap of $11.94 billion, a PE ratio of 13.78, a PEG ratio of 0.50 and a beta of 0.80. The firm has a 50-day simple moving average of $181.36 and a 200 day simple moving average of $176.50.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.57 by $0.25. The firm had revenue of $3.58 billion during the quarter, compared to analysts' expectations of $3.52 billion. DaVita had a negative return on equity of 215.05% and a net margin of 6.49%. The company's revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.51 EPS. Research analysts forecast that DaVita will post 14.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DaVita

Several institutional investors have recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC boosted its holdings in shares of DaVita by 25.3% during the third quarter. Chicago Partners Investment Group LLC now owns 3,818 shares of the company's stock worth $701,000 after acquiring an additional 772 shares during the period. Provenance Wealth Advisors LLC bought a new position in shares of DaVita during the third quarter worth approximately $30,000. Oregon Public Employees Retirement Fund lifted its holdings in DaVita by 5.1% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 4,147 shares of the company's stock worth $725,000 after purchasing an additional 200 shares during the last quarter. Pinkerton Wealth LLC acquired a new stake in DaVita during the 3rd quarter worth approximately $225,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in DaVita in the 3rd quarter valued at $1,874,000. 90.12% of the stock is owned by institutional investors.

More DaVita News

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Strong quarterly beat: DaVita reported adjusted earnings of $3.82 per share, above the $3.57 FactSet consensus, while revenue rose 4.6% year over year to $3.58 billion, exceeding the $3.52 billion estimate. DaVita Q3 adjusted EPS earnings flash
• Positive Sentiment: Kidney Care and international growth supported results: Earnings increased sharply from the prior-year period, with reported net income attributable to common shareholders rising 48.3% to $222.9 million. The company’s integrated kidney care operations were highlighted as a key growth driver. DaVita Q3 earnings beat and growth
• Neutral Sentiment: Profitability was mixed: Operating profit declined 1.3% year over year to $499.3 million, suggesting that higher costs and margin pressure offset some of the revenue growth. Cash flow from operations also fell to $518.8 million, while capital spending totaled $159.5 million. DaVita Q3 2026 financial results
• Negative Sentiment: $62 million China charge weighed on sentiment: Reports indicate a charge related to China reduced the quality of the quarter’s headline beat and raised concerns about potential additional costs or operational issues. DaVita China charge and Q3 earnings
• Negative Sentiment: Additional overhangs include insider selling and a legal investigation: Recent data shows several insiders, including Berkshire Hathaway and DaVita executives, selling shares, while Pomerantz LLP announced an investigation on behalf of investors. Neither necessarily indicates wrongdoing, but both developments may add near-term uncertainty. Pomerantz DaVita investor investigation

About DaVita

DaVita Inc NYSE: DVA is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.